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Abstract
Background: Parents of children with rare diseases often face uncertainty about diagnosis, treatment, and costs
associated with healthcare for their child. Health insurance status impacts each of these areas, but no U.S. study has
explored parents’ perceptions of the health insurance impacts on their child’s care. This study aimed to qualitatively
explore how these parents navigate the complex health insurance system for their children and their experiences in
doing so.
Methods: Semi-structured interviews were conducted with parents of children with metachromatic leukodystrophy
(MLD) and spinal muscular atrophy (SMA), chosen for specific disease characteristics and orphan drug status. Participants were recruited via e-mail through patient advocacy organizations between September and December 2018.
Interviews were conducted via Skype, were recorded, and professionally transcribed. Modified grounded theory was
utilized as a methodology to analyze transcripts in an iterative process to determine themes and sub-themes based
on participant described experiences.
Results: Major themes and subthemes that emerged across the 15 interviews included: (1) difficulties obtaining
secondary insurance based on state eligibility criteria; (2) difficulty accessing needed healthcare services; and (3) need
for repeated interactions with insurance representatives. The absence of clearly documented or widely recognized
clinical guidelines exacerbated the difficulty accessing care identified as necessary by their healthcare team, such as
therapy and equipment. An explanatory model for parent’s experiences was developed from the themes and subthemes. The model includes the cyclical nature of interacting with insurance for redundant reauthorizations and the
outside support and financial assistance that is often necessary to address their child’s healthcare needs.
Conclusions: With complex health conditions, small setbacks can become costly and disruptive to the health of
the child and the life of the family. This study suggests that patients with rare diseases may benefit from time limits
for processing coverage decisions, increasing transparency in the claims and preauthorization processes, and more
expansive authorizations for on-going needs. Additional studies are needed to understand the full scope of barriers
and to inform policies that can facilitate better access for families living with rare diseases.
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Background
Rare diseases are defined in the United States as conditions with less than 200,000 cases [1, 2]. The National
Institutes of Health (NIH) currently lists over 6,800 rare
diseases that together impact between 25 to 30 million
Americans, 60% of whom are under 18 years of age [3].
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Rare diseases are often difficult to diagnose, have few
treatment options, and limited research on the natural
history of the condition. These challenges, along with an
inadequate number of healthcare providers familiar with
rare diseases [4–9] and the financial strain generated by
rare disease care often leave parents of children living
with rare diseases feeling isolated and uncertain about
the disease progression [5, 7, 10–13].
The knowledge gaps about rare diseases and related
care often places parents in the role of disease expert and
care coordinator [6, 14–16]. They often have to identify
services across siloed healthcare and social service agencies [12, 16, 17] and may need to educate some healthcare providers, who can serve as gatekeepers to certain
treatments or services [15]. To avoid large out-of-pocket
bills, parents must interface with health insurance representatives to advocate for coverage of services.
Parents’ role in interfacing with insurance representatives may be the most complex aspect of their advocacy
role. Like healthcare delivery systems in the U.S., the
insurance system is highly complex, fragmented, and eligibility for plans varies based on sociodemographic factors, geography, and employment status [18–21]. In 2016,
49% of Americans purchased health insurance through
employer sponsored plans (private), 35% were insured by
government-sponsored health insurance plans (public),
and 9% were uninsured [22]. The largest public insurance
programs are Medicare and Medicaid. All individuals
over the age of 65 and those with long-term disabilities
are eligible for Medicare [23] while Medicaid is available
for people with low-income levels or certain disabilities.
Eligibility for Medicaid is determined at the state level
and in 2020 49.5% of enrollees nationwide were children
[24].
Access to healthcare for children with rare diseases
has become even more complicated as health insurance
companies have sought to decrease healthcare costs
at the individual and systems level. Insurers’ strategies
for decreasing costs include managed care plans, which
require patients to pay more if they receive care outside
of a specific network of healthcare providers; requiring patients to pay a greater portion of costs; and having
‘tiered’ drug formularies that make some medications
far more expensive than others [25–27]. Children with
a rare disease diagnosis may need numerous visits to
specialists in multiple locations [8] and a condition may
only have a handful of experts or specialty centers able to
manage the disease, who are unlikely to be in a families’
approved network of healthcare providers [9]. Because
private insurance is tied to an employer, parents of children with rare diseases often restrict their employment
choices based on the health insurance a given employer
offers [13, 28, 29].
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A recent U.S. study estimated that direct and indirect
costs related to just 379 rare diseases represented economic costs of nearly $1 trillion in 2019 [30]. Based on
their disability status, individuals may qualify for multiple
insurance programs, or due to high out-of-pocket costs
they may choose to purchase supplemental insurance,
resulting in ‘double’ and ‘triple’ coverage. Orphan drugs
are one aspect of care costs for some patients. Roughly
300 rare diseases have a Food and Drug Administration
(FDA) approved orphan drug [31] and there has been
much criticism of the financial incentives and price for
these treatments [32–35]. A study of U.S. health insurance plans showed that orphan drug coverage is inconsistent across exchange plans, plans available for anyone
within that state to purchase [36]. Despite the high cost
of orphan drugs, the impact of these treatments can be
life-changing for families [37].
There is a complicated balance between decreasing
healthcare costs and meeting patient needs. To date,
there have been no published studies of parents’ perspectives on their experiences with healthcare insurance
companies or studies that seek to understand how health
insurance policies may impede health care for patients
with rare diseases. The aim of the study was to qualitatively explore rare disease parents’ experiences with
health insurance for their child living with a rare disease,
to identify potential barriers to optimal care, and to generate recommendations to address barriers identified.

Methods
Overview

The heterogeneity of rare diseases makes it difficult to
identify a “typical” disease. Parents of children with
MLD and SMA were selected for inclusion in this study
because of disease similarities and orphan drug status
differences for the two diseases. Both diseases have an
identified genetic mutation and varying degrees of severity within the disease [38, 39]. Both conditions impact
motor function, which may require physical therapy or
supportive equipment to aid mobility [38–41]. SMA can
impact the ability to breathe and eat, which may result
in the need for feeding tubes or monitoring from a pulmonologist. MLD causes progressive deterioration of
intellectual functions, seizures, an inability to speak,
blindness, and hearing loss requiring a range of therapists and specialists to provide on-going care [39].In
2016, the drug nusinersen was approved by the FDA to
treat SMA after clinical trials showed that it can improve
motor-milestone responses for some users [37, 42]. Stem
cell transplantation may be appropriate for some patients
with MLD, but at the time of the study, there was no
approved orphan drug available [43]. Additional MLD
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and SMA care for most patients focuses on symptom
management.
In this qualitative study, semi-structured interviews
were conducted with parents of children with one of
these two rare diseases, aiming to better understand how
parents’ experiences related to health insurance may
impact children’s care. Modified grounded theory principles were applied through data collection techniques,
an iterative process of data analysis and coding, and
theory generation of a model to further tell the story as
described by parents [44–46].
Sampling and recruitment

Participants were eligible to participate in this study if
they were over 18 years of age, a resident of the U.S., and
the medical or legal guardian of a living individual diagnosed with SMA or MLD. Recruitment messages that
included a link to the study pre-participation questionnaire were provided to patient organizations, that represented each rare disease; the organizations then emailed
the messages to their members (roughly 7,200 SMA and
600 MLD families) and shared the message and links
to the screening questionnaire on their organizational
Facebook pages between September 2018 and December 2018. The questionnaire determined eligibility, collected contact and basic demographic information, and
identified options for scheduling an audio interview via
Skype. Although several interviewees offered to contact
people they thought might be interested in participating,
no referees contacted the study staff directly. It is possible that some of the people recruited through Facebook
or email had heard about the study through peers but we
did not collect these data [47]. This study was approved
by the University of Massachusetts Amherst Institutional
Review Board.
Data collection and analysis

Interviews were conducted by TP using a semi-structured interview guide that included questions related
to interviewees’ experiences with health insurers. Interviews were audio recorded and professionally transcribed
verbatim with participants’ permission. Interview transcripts were analyzed using NVivo 12 software [48]. The
section headers of the interview guide, such as “cost sharing” and “navigation” served as initial broad coding categories. The first author read the first several transcripts
to gain a sense of understanding of the data as a whole
then proceeded with iterative line-by-line open coding of
2–3 transcripts at a time before conducting the next set
of interviews. Constant comparative analysis continued
as new interviews were conducted; memos were used to
identify emerging themes and to begin to build theory
regarding parents’ experiences [45, 46].
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Recruitment ended when data saturation had been
reached, meaning no new themes emerged over three
consecutive transcripts [49]. A research assistant (RA)
trained in qualitative methods independently performed
line-by-line coding of four transcripts after interviews
were completed and side-by-side comparisons were performed between the work completed by the author and
the RA to assess reproducibility of the codebook. Differences were resolved through discussion and the final
side-by-side comparison found less than 5% difference
between the two coders.
Axial coding was performed as the analysis progressed,
continuing to build theory and construct a model that
demonstrated how parents experience the health insurance system and factors that contribute to their ability
to both navigate the system and gain access to care [45].
The model was developed through theory generation by
exploring the linkage between the key themes and subthemes and organizing them thematically to provide context to the experience, including the addition of external
factors that are established elements for understanding
the context of access to healthcare in a particular setting;
accessibility, availability, acceptability, and quality [50].

Results
Participant characteristics

A total of 15 parents participated in the study; four had
one child with MLD, 10 had one child living with SMA,
and one parent had two children living with SMA. Every
child had health insurance through at least one parent’s
employer. Nine patients were also double or triple-covered through a public insurance program such as Medicaid. Additional participant characteristics can be found
in Table 1. Interviews lasted an average of 29 min.
Major themes

A total of seven major themes were identified: (1)
Involvement; (2) Support; (3) Obtaining insurance; (4)
Interacting with insurance company representatives; (5)
Accessing care through insurance; (6) Financial assistance; (7) Individual factors. Themes are described in
detail below with illustrative quotes and additional quotes
are reported in Table 2. Sub-themes, including disputes
and emotions, provide additional detail to the experience
and the model. All quotes are reported using the patients’
disease and state of residence to protect privacy.
Involvement

Navigating insurance correctly was viewed as a necessity.
However, in most responses, individuals did not differentiate between their public and private insurance experience. Individuals expressed confusion related to health
insurance documentation, such as benefit descriptions.
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Table 1 Participant characteristics
Characteristic

N

%

Child’s diagnosis
Spinal muscular atrophy (SMA)

11

73.3

4

26.7

Mother

14

93.3

Father

1

Metachromatic leukodystrophy (MLD)
Relationship to patient (child)

6.7

Mean (SD)
Parent age

39 (9.26)

Child age

6 (5.62)

Time to diagnosis (months)

Minimum–maximum
31–67 years old
6 months to 21 years old

13.53 (14.3)

0 (Prior to birth)- 48

N

%

Region
South (Maryland, Virginia, Tennessee, Texas)

6

40.0

North (New York, Massachusetts)

3

20.0

Mid-West (Illinois, Michigan, Minnesota)

5

33.3

West (California)

1

6.7

Insurance type
Employer sponsored

15

100.0

Medicaid

6

40.0

Medicare

1

6.7

Children’s health insurance plan

2

13.3

Medical assistance program (state or county)

2

13.3

Education
High school diploma

1

6.7

College degree

8

53.3

Graduate degree

6

40.0

Currently employed
Yes

11

73.3

No

4

36.7

Some people wanted help finding information, while
others did not believe clearer answers existed or that
insurance would provide them. Individuals spoke about
the iterative process of learning the system and piecing
together information over time.
You know, we have talked to a lot of organizations
and individuals over the course of her 11 months
of life, but I think it has really fallen to us to educate ourselves. We’ve probably talked to 50+ people
from advocacy groups, to disability coalition, to lawyers, to case workers, to social workers to, you know,
political advocates, and each person has provided
us with a little piece of information, but it’s kind of
remained up to us to sort of figure out overall how to
navigate the system. (SMA, TN)
Parents felt obligated to keep detailed notes, stay
actively involved in learning about their child’s disease,

and ensuring care needs were met. Even parents who
described a more passive approach to seeing what happens as claims moved through the system, still described
taking actions, such as sending claims back to providers
or pre-writing authorization letters.
Support

Disease specific organizations, disability organizations,
social services agencies, and medical professionals were
often seen as a valuable starting point for emotional support and knowledge. Employer benefits managers or
members of the leadership team intervened to get benefits on behalf of some of the families. Most individuals
spoke about the importance of peer support. This often
came from patient communities, including social media.
There was at least one time where I was receiving
incorrect information from our insurance company.
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Table 2 Additional illustrative quotes
Theme

Quote

Obtaining insurance

When we tried to get Medicaid, there are literally hoops that you have to jump through to get them into a Medicaid program, at least in the state of Texas. So, you could either go down to the waiting list that took X number
of years – I mean, we’re still on some of these other lists, and she was diagnosed four years ago, so a lot of these
lists are, you know, 10, 12, 15 years long, for waiting lists… But you can try the Writer 28, and you have to meet
at least two criteria. (MLD, TX)

Obtaining insurance

There was another mom that had just, on the advice of a doctor, had moved from Arkansas to Texas because of
the Medicaid benefits. (MLD, TX)

Interacting with insurance company If you’re trying to manage – you have other children and you work and you’re trying to keep a household and
representatives
what not, it’s hard to sit on the phone for 30 min waiting for someone to help you, and then, you may get
redirected five times. (SMA, CA)
Accessing care

For her, you might need a drug that is proven for cystic fibrosis, but we know for a fact that she has some of the
same lung issues, but we may not be able to get the insurance to cover that equipment or that drug because
we don’t have the background that says, "Oh yeah, they will work for MLD too." (MLD, MN)

Accessing care

When we need things, we’ve not really had any pushback on them saying, “No, you know you all don’t get that.”
But I don’t feel like we’ve really asked for crazy things that aren’t necessary either. (SMA, TX)

Accessing care: disputes

So we were under the impression that we were being covered, but we weren’t, because our insurance company
had a cap we were never made aware of [despite prior inquiries], and therefore, I fought very long to get over
$3,000 worth of physical therapy appointments covered by the hospital. (SMA, TX)

Financial assistance

Another device that was not covered is an Eye Gaze communication device was not covered by insurance, and
thankfully, the school system provided that for my son while he was in preschool and not physically attending
a school yet. So, if we had lived in a county or a district that was unable to do that, we would still not have a
way for our son to communicate with us in an understandable way for everyone else. (SMA, MD)

Individual factors

I’m not sure about things like PT and OT, and the reason I don’t know about that right now is because her PT and
OT needs currently are covered by our state’s early intervention program, and so, there is no cap for those, so I
don’t know. When she reaches the age of three, that may become more of an issue for us. (SMA, TN)

Individual factors: emotional factors

She has a genetic disease– we didn’t know, we didn’t anticipate it, it’s not something that happened because
of malpractice or because of negligence or anything. But I certainly want everybody to be able to take care of
their kids, their sick kids, as well as we can. (SMA, IL)

Individual factors: emotional factors

It goes back to walking around in somebody else’s shoes and trying to figure it out. It is not like we are trying to
take advantage of anybody when we have kids with rare genetic illnesses. It is very difficult. (MLD, MN)

I was put on hold, because they were trying to figure
things out, and I went online, and I said, “Hey, who
here has this insurance company and was told that?”
and literally 30 seconds later, another mom wrote in
to say, “We do. This is what I was told, and this is
what you need to tell them.” So, by the time I got off
hold, they were like, “Here.” I told them, “Here, this is
what it is. No.” I was like telling the insurance company, “this is what it really is.” (SMA, TX)
Obtaining insurance

All individuals stated their child had never been uninsured.
The desire to have immediate coverage for treatments,
specifically nusinersen, led one mom to decline anesthesia
during childbirth to ensure she could complete the social
security paperwork and email her insurance company following her child’s birth. Some participants had difficulty
obtaining secondary insurance, which they attributed to
state-based eligibility variations or long wait times. MLD
parents stated they did not qualify for secondary insurance before they received the diagnosis, but their primary
insurance denied coverage for diagnostic testing. Public
insurance was described as either a way to improve access

to care, such as nursing services, or a way to pay costs
associated with private insurance. For example, Medicaid
benefits covered copayments associated with employer
sponsored plans and in some states, Medicaid paid for a
child’s monthly health insurance premiums.
Almost every single state in this country has a
waiver that allowed medically disabled children to
get on the state Medicaid system, so that they can get
access to all of those services, regardless of parental
income, and our state does not have that, so that has
been incredibly difficult for us, and has been a major
barrier in getting her care, you know, nursing, and
some of the equipment that is only covered by Medicaid, it’s not covered by private insurance. (SMA,
TN)
Employment was a critical factor in obtaining insurance for all participants, but many described the limitations based on the size of their employer or the quality
of the plans that were offered. Health insurance was cited
as a determining factor for any employment decisions,
including one individual who, despite her age, is working to “pay my fair share”. Individuals spoke about fears
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related to losing a job and repercussions for being “too
costly”, despite the legal ramifications of discrimination.
Trying to figure out what insurance we should get
was, the hardest part, because I was too scared to
call the insurance directly. Like, each of us [both
parents] didn’t want to just call them and ask them,
because we thought, we might get fired from our
jobs, because they would find out how much it costs,
because we had heard horror stories… There are
laws on the book that protect you, so they can’t fire
you, but it happens. Like, all of a sudden, your job
just isn’t there anymore, you know? (SMA, VA)

Interacting with insurance company
representatives
Many individuals tried to pre-plan their short and longterm care health needs and work with insurance to see
what would be covered in a specified timeframe to anticipate denials or reauthorization periods to limit disruptions in care. Everyone described frustrations related to
calling insurance companies, but those whose children
were asymptomatic due to current treatment regimes,
stated they did not have to do this often. Individuals who
had more complex health needs described the time they
spent each week on the phone. When individuals contacted the insurance company, they often had to navigate
automated systems, first-tier customer service representatives, and multiple people before finding the appropriate
person to provide an answer. The frustration was exacerbated by the complications of daily life.
Then that means I’m suctioning his trach [tracheal
tube] and having somebody on headphones [from
insurance] and helping him to read his guided reading book. You know, that can make it tricky… how
time-consuming it is to navigate. (SMA, MD)
Individuals described times when they felt that they
received different answers from different people or mentioned inconsistencies in documentation online versus in
printed materials. Although a few felt that they understood the benefits, the majority felt that vague language
or inconsistencies were purposeful. After an on-going
dispute where the family and their hospital believed the
insurance company purposefully provided inconsistent
information, one mom resorted to threatening to go to
the media, after that, the issue was handled in 24 h.
The left hand doesn’t know what the right hand is
doing, and that makes it really tricky to navigate,
because, you know, it puts more pressure on the parents or the caregiver to do their due diligence, where
I feel like it shouldn’t necessarily be all on us to do it.
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(SMA, TX)
Correctly submitting documentation was described as a
team effort between parents and medical providers. Providers submitting claims to the wrong insurer or incorrectly submitting claims using the wrong code could
result in claims sitting in limbo for months or denials of
routine claims. Certain treatments, referrals, and equipment required reauthorizations or repetitive documentation to continually prove on-going medical necessity.
She doesn’t have something that’s just going to get
better or go away. She’s always going to have it; so I
just don’t know why we have to keep running through
the same circles for the same thing. (SMA, MI)
Some insurance companies provided caseworkers or
navigators proactively, while other participants only
received caseworkers after requesting one. Caseworker
quality was highly variable according to participants but
often improved if the caseworker stayed with the family
over time. Individuals felt that these individuals had the
potential to help navigate the terminology, documentation, or provide cost saving options. People wanted to
be treated with a sense of respect. When they did not
feel heard or if they were treated like they were trying to
“game” the system, it eroded trust, reinforced the need to
be vigilant, and to go into “mama bear advocate mode”.
I mean, I hate it [interacting with insurance], but it
has to be done, because we can’t afford to not have
it be done right, so we just have to continue to keep
this documentation of every call and every time and
what they said, because I feel like I’m more organized than they are, and I feel that I have to be,
because my daughter’s definitely worth it, so this is
where we have to be. (SMA, TX)
Accessing care through insurance

Participants reported the greatest barriers to coverage
related to equipment, nursing care, therapy, and outof-network providers. Those who were aware of tieredfinancing schemes indicated their child’s providers were
always on the highest tier where they would need to pay
the most out-of-pocket. A common sub-theme was disputes when insurance would deny coverage to care which
would then force individuals to interact with insurance
again. For example, seeking out of network care was
discouraged by insurance, but many parents expressed
the frustration of not being able to seek disease specific
expert care. As one said,
It was recommended that we go to Columbia Children’s Hospital, where they have an SMA clinic, but
originally, we were denied coverage there because
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it was out of network, and basically I said, “Why?”
They said I have a pulmonologist center up closer
to home… but we would argue there is not an SMA
specialist out here. (SMA, NY)
The insurance company’s representative’s comprehension
and understanding of the medical situation seemed inadequate to most participants. Due to the lack of knowledge of the disease, parents wanted insurance to try to
understand their case history or defer to the medical professionals related to their care needs when making coverage decisions.
She has to be on continuous pulse oximetry monitoring, which we were denied multiple times, until our
doctor wrote for oxygen, and she doesn’t need oxygen. In fact, that’s kind of contraindicated in SMA,
but the insurance company would not allow us to
have a pulse oximeter to monitor her oxygen level in
her blood and her adequacy of ventilation, until she
was written for oxygen. (SMA, TN)
Providers are responsible for submitting healthcare
claims to insurance companies so parents whose children
were covered through multiple plans could not always be
sure where claims were submitted until they received a
statement of benefits, a description of potential out-ofpocket costs, or a bill. Inconsistencies in what parents
were ultimately financially responsible for across similar
claims necessitated following up on each statement of
benefits to avoid unexpected bills. Some aspects of care
also required additional steps to avoid out-of-pocket
costs, for example, one parent said that every month
she must call the durable medical equipment company
directly to ensure that the claim will be submitted to
insurance, if the company auto-ships the company would
not charge insurance and she would be responsible for
the bill.
Nurses and therapists provided information, respite
help for parents whose children often need around the
clock-care, and helped children hit medical milestones.
Parents were frustrated by the minimal amount of nursing care and therapy that was covered by insurance,
which often seemed inadequate or disrupted care patterns that were showing mobility gains. Multiple people
spoke about the annual process of trying to get clarity on
coverage allowances, only to be told different information
or lose access later.
Some parents felt that their total out-of-pocket costs
were reasonable considering the scope and total cost of
the care needs. This often came from individuals who
had additional coverage, such as employment perks
that covered fees or who were on secondary insurance
programs. Five individuals were aware of out-of-pocket
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maximums for the year, four could name what month
they met that maximum. There was a split between
individuals who just referred to “bills” and those who
could recall the exact amount for premiums, deductibles, copays, and coinsurance. Those who had deductibles said they ranged from $1,000 to $7,500 for their
family and spoke about how quickly they met them.
The cost of equipment, drugs, therapy, and out-ofnetwork services were described as the most expensive
components of care. None of the individuals received a
denial for nusinersen, however, many were concerned
about the waiting period before the cost was covered
or before they received the approval for the drug. These
types of services often had cost-sharing mechanisms,
but the patient’s portion was still quite large. As one
participant said, “A 10% copay on a $150,000 per year
bill is prohibitive for most people”. (SMA, TN).
A few individuals spoke about shifting formularies,
gatekeeping requirements, networked providers, and
benefits that sometimes changed how the individual
could access care. Sometimes these changes would be
related to eligibility shifts, such as a provider who was
included in Early Intervention, but out-of-network
when the child aged-out. Many people discussed the
concern about the health consequences of the delays or
denials of the insurance company, especially the potential for worst health outcomes or lost opportunities,
such as clinical trial participation. Many expressed that
if a doctor indicated that something was medically necessary, families should have an affordable way to access
it. For example, one participant said,
It shouldn’t be about, “Oh, sorry, you can’t have
this because it’s too expensive.” Well, but that’s
what the patient needs. So, if that’s what the
patient needs, find a way to make it more affordable so that they can have it. (SMA, CA)
Participants had different expectations about what
should and should not be covered by health insurance.
Some individuals were narrowly focused on specific
medical costs, while others looked at the full paradigm
of care and supportive technologies, such as powerchairs and adaptive beds, that impacted overall health
outcomes.
Now, I am trying to get some equipment for her mattress and I am just trying to get it paid for with the
proper paperwork signed and everything… I feel if
I did the financial analysis on how much it costs to
take care of a wound, they would certainly rather
pay for the mattress, it is 300 bucks instead of the
$3,000 that it is going to cost if I have to put her in
the hospital time and time again. (MLD, MN)
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Financial assistance

Insurance was described as one piece in the larger financial structure. Almost every SMA patient received nusinersen through the clinical trial or the drug company’s
copay assistance program. Many utilized equipment
shares, local charities, small grants, or personal fundraisers to meet additional needs. If an individual did not
access other financial assistance programs they indicated
either none were available, they were saving it for a future
need, they did not have time to complete the applications, or they believed others had greater need. Responsibility fell to parents to identify the source of funds and
decide the timing of the of the application.
And I really think that when you look at someone’s
care needs you know insurance is one part of it but
it’s really like trying to understand all of the benefits
including insurance that they are entitled to and
how all of those pieces need to work together. (SMA,
MN)
Individual factors

The child’s health was a sub-theme within individual factors. Some parents reported that after their child took
nusinersen they no longer had on-going care needs. In
these cases, parents were less likely to have on-going disputes with insurance companies and were more focused
on the initial struggle to access the drug.
When asked if individuals were satisfied with their
insurance, many said yes, despite describing challenging experiences. One respondent stated, “That’s kind
of a trick question.” A few reflected on the importance
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of taking care of each other. Individuals also looked at
their own privilege related to education, support, and the
severity of their child’s condition when reflecting on their
experience.
A family that the parents are working two jobs and
they are barely able to look over their bills and they
just have time to pay them, if they don’t have time
to scrupulously look through what is actually being
billed, there’s been times where we’ve had more than
$1,000 of a bill for something that was billed incorrectly, and then that turns out to be kind of an insurance nightmare (SMA, MD)
People spoke about how the coverage they could access
would impact their life decisions, such as having more
children. Many expressed that things were not fully in
their control and they only had so much bandwidth to
continually fight. The political climate and fears of losing
protections for preexisting conditions weighed heavily on
many. A few people spoke directly about their own mental health.
It goes back to walking around in somebody else’s
shoes and trying to figure it out. It is not like we are
trying to take advantage of anybody when we have
kids with rare genetic illnesses. It is very difficult.
(MLD, MN)

Model
An explanatory model of health insurance experiences of
parents of children with rare diseases in the U.S. (Fig. 1)
was developed using themes generated by analysis of the

Fig. 1 An explanatory model of health insurance experiences of parents of children with rare diseases in the US
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interviews and previously established external factors
that affect healthcare access. Although the model was
created based on the responses of parents, it could also
apply to any primary caregiver of a rare disease child. The
model demonstrates how the parent needs to be involved
throughout the process and the parent’s focus on their
child’s long-term health outcome. Characteristics related
to the parent and child are displayed in light blue. Areas
in green represent the actions taken by the parent to
navigate the insurance system to ultimately access care
on behalf of their child to influence aspects of care and
overall health outcomes. The parent’s ability to navigate
the system was impacted by individual factors such as
demographics, location, employment, health literacy,
and emotional factors. Emotional factors such as uncertainty, urgency, and responsibility impacted the level of
“hands-on” involvement parents exhibited while navigating insurance. Established external factors of accessibility, availability, acceptability, and quality [50] impact an
individual’s health quality and the opportunity to obtain
insurance. Emotional and knowledge support was provided by external forces throughout the process, but it
was still up to the parent to coordinate care.
The domains in the model identified in dark blue,
obtaining, interacting, and accessing, refer to direct
parental interactions with health insurance companies.
Obtaining insurance can be complicated by eligibility
constraints and options within exchanges or employers. Interacting with the insurance company required
time and complex documentation and was categorized
by frustration in the redundancy of needed reauthorizations, incomplete information, and sub-par knowledge
by the company representatives. Accessing care through
insurance describes the approved coverage of healthcare
services an individual receives through health insurance.
However, disputes may arise if services are denied or are
too costly for patients. Additional financial assistance
may be sought outside of the health insurance system,
such as drug co-pay or personal fundraising programs.
The result of this additional access or delays in care can
have a positive or negative impact on the child’s health
outcomes. These changes, either improvements, such as
access to an orphan drug or a new diagnosis, or medical
setbacks, such as an additional hospitalization, can result
in eligibility changes or the approach a parent may take
when interacting with the system.

Discussion
Parents in this study reported a need to meticulously
track time-consuming interactions with insurance company representatives, and often felt that they are missing key information about coverage allowances and what
care was covered for their child under their insurance
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policy. A single health insurance policy was rarely enough
to cover the cost of all healthcare needs for their child,
which resulted in parents viewing access as a web of different policies and social service supports.
In this study, parents of children with both SMA and
MLD had to interact extensively with insurers to gain
access to services and products seen as medical necessities, which is consistent with previous findings [15, 16,
28]. None of the SMA parents spoke about delays in diagnosis and some SMA parents had learned of their child’s
diagnosis in the prenatal period. Early establishment of a
diagnosis made initial interactions with insurance companies somewhat easier for parents of children with SMA
compared to parents of children with MLD, which often
takes more time to diagnose. Parents, with recommendations from medical professionals, felt that they were
looking at long-term needs and outcomes, but parents
felt that insurers were more focused on more immediate utilization controls and reducing access to expensive
drugs and services. Both MLD and SMA parents felt that
they had to educate insurance company representatives
about their child’s disease and justify care needs. However, it appeared that insurance companies had fewer
established guidelines for MLD, which necessitated more
intervention from allied health professionals or employers working with parents of a child with MLD to facilitate access care when compared to parents of a child with
SMA.Previous studies speak to the lack of knowledge
among medical professionals for rare diseases [4, 7], but
lack of knowledge within insurance companies has not
been described. The lack of knowledge parents perceived
by insurance representatives led to greater frustrations
when insurers did not consider the medical benefits and
long-term cost savings of access to equipment, therapy,
and diagnostics. This is consistent with studies that have
indicated barriers to diagnosis and diagnostic testing for
rare diseases [7, 51]. Parents in this study expressed frustration that insurance representatives did not understand
the importance of seeing disease experts or maintaining
treatment schedules set-up by these specialists.
The use of patient navigators from within insurance
companies to help people navigate the clinical aspects
of the healthcare system have not systematically been
described in the literature. Navigators are often social
workers or medical professionals who can help expand
coverage, provide referrals, provide support, help navigate the system, and provide care coordination [52–54].
There are a number of studies dedicated to their use for
people with chronic conditions, the majority of which
focus on cancer [52, 55]. One mother stated that hospital navigators “can help you while you are inpatient
and actively in treatment, but we don’t have that sort of
thing for just the after mess [on-going medical needs]
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with leukodystrophy.” These programs show promise for
increasing access and addressing health disparities in
chronic conditions and may benefit rare disease parents
[54, 55].
Many inequities exist in the U.S. healthcare system
and, although the extent has not been fully determine,
are likely to negatively affect individuals living with
genetic or rare diseases similarly to other populations
of patients [56]. Rare diseases are not limited to certain sociodemographic populations and social determinants of health such as income, race, community, access
to services, social supports, and education are likely to
affect the timeliness and quality of care patients receive
[57]. Investing in a just healthcare system that addresses
structural and systemic barriers will be beneficial to all
[58–60].
There is a growing dialogue on the need to address the
negative impact of the high costs associated with expensive treatments [30, 61]. In rare diseases, there is additional criticism related to the high price tag of orphan
drugs [34, 62–64]. Study participants were not always in
agreement related to which healthcare costs should be
covered by the system, especially for supportive technologies or medical devices that individuals believed could
prevent future healthcare needs. Inequities in the U.S.
system, growing criticisms around the cost of orphan
drugs, and additional calls for addressing unmet need
will require additional healthcare debates and new policies [30, 59, 61–65].
Policy considerations

Individuals in the U.S. managing chronic conditions,
such as musculoskeletal problems or lung conditions,
may face access issues that can lead to unmet health
care needs [66, 67]. The concerns with access and high
costs of care are similar between those with chronic
conditions and with rare diseases. Additionally, parents
of children with other common chronic diseases in the
U.S face challenges similar to parents of children with
a rare disease related to the need to coordinate healthcare while navigating evolving healthcare needs [68].
Although caregivers or patients with chronic conditions are encouraged to learn about their disease and
its treatment so that they can self-manage their disease
between visits with physicians, patients with rare diseases or their caregivers must often be the expert on all
nuances of the disease because primary care providers
are not always knowledgeable enough about the condition to provide key aspects of coordination [11, 15, 16].
Difficulties in determining a diagnosis are less common
for children with other chronic diseases, an issue that
can complicate gaining access to targeted healthcare
programs, such as Medicaid and Medicare for parents
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of children with a rare disease [7, 30]. Investing in programs that could lead to more timely diagnosis, including access to genetic testing could benefit patients [13,
51]. Additionally, expanding access to Medicaid and
the resources to limit the time necessary to review an
application could result in additional avenues to obtain
insurance.
Insurers are unlikely to be knowledgeable about all rare
diseases, but if insurers were to provide a clearer framework for assessing medical needs or employed specialists who are trained to work with complex care cases
in a respectful way it would improve the parent experience. Some insurers utilize this type of specialist and
patient navigators for chronic care patients have helped
to improve patient outcomes, address disparities, and
reduce the cost of care for patients [54, 55, 69, 70]. However, little, has been done to evaluate the effectiveness
of patient navigators for improving outcomes and costs
among rare disease patients. Rare disease specific navigators can also more appropriately provide information
about the landscape for additional financial assistance
opportunities.
This study adds to the literature that documents the
importance of prior authorizations being evidence based,
timely, and incorporate the expertise of medical professionals familiar with the disease [14, 16, 71]. Policies
should focus on increasing the transparency of the preauthorization and claims process and establishing time limits for processing coverage decisions [5, 15, 71]. Universal
authorizations for on-going needs or specialists would
decrease the burden on families and medical providers.
Individuals with compelling needs to see a disease specialist should have an opportunity to seek waivers from
out-of-network care cost restraints or to seek expert
opinions in a cost-effective way, which may be leveraged
through the increased use of telemedicine. More research
into the natural history of rare diseases and establishing medically recognized treatment guidelines would
improve evidence-based care for patients, especially if
insurance was required to provide coverage for the services necessary to follow those guidelines.
Rare disease patients and families across the globe and
different healthcare systems have expressed challenges
finding care and experts knowledgeable in their disease
[6, 7, 16, 61]. However, some countries have made more
significant attempts to address these problems by establishing rare disease centers of excellence and national rare
disease plans [72, 73]. There are some similar initiatives
through the NIH and patient advocacy organizations
at the state and federal level that could be supported to
further facilitate access to care [1, 74]. Additional awareness and research related to the needs for families living
with rare diseases can further highlight additional policy
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Table 3 Major themes and policy recommendations
Major themes

Primary obstacle/barrier

Policy recommendation

Obtaining insurance

Insurance eligibility differences across states and wait
lists to obtain public insurance can limit access to
certain types of care
Life decisions such as employment and geographic
location are tied to healthcare needs

Consistent mechanisms for patients living with rare
diseases to enroll in insurance programs
Universal coverage programs that are not tied to employment
Additional resources in Medicaid to reduce enrollment
wait times
Programs to help patients access diagnostics, including
genetic testing

Interacting with insurance company representatives

Difficulty getting clear and consistent answers related
to coverage
Time intensive and redundant process to cover ongoing care needs
Lack of knowledge amongst insurance company
representatives about the medical condition and care
needs

Insurance staff trained in dealing with rare diseases
A better framework to assess rare medical needs
Assigned caseworkers or patient navigators within
insurance and a direct way for parents to contact their
representative to increase consistency
Clear and transparent documentation related to coverage benefits
Increased transparency in the claims and prior authorization processes to decrease the time and understand
the status
Time limits for coverage decisions
Universal authorizations for on-going needs to decrease
redundancy

Accessing care through insurance Changes from year to year resulted in different out-ofpocket costs and an ability to plan for other healthcare assistance
If coverage was denied, parents were forced to interact
with insurance again to dispute the claim
Some aspects of care were seen as medically necessary
by providers, but were not covered under insurance
Cost-sharing mechanisms, even if modest, could be
prohibitive

Consistency of coverage across plan years and clarity
around changes
Published fee schedules and costs
Waivers for out-of-network care so individuals can access
diseFinancial assistance or caps on total out-of-pocket
costs
ase experts
Approvals for telemedicine that are not subjected to out
of network care restraints

Financial assistance

Additional financial assistance was often necessary to
cover healthcare needs
From the parental viewpoint, insurance and other
assistance were an interconnected web to cover
needed care
Some programs were dependent on age or geography

Centralized location for information about other financial
assistance programs
Rare disease specific navigators

Involvement in insurance

Parents were responsible for learning the system and
available options
Health literacy and overall comfort interacting the
system could impact mental health and stress
Parents felt they needed to devote a lot of time to
understanding the system, especially to prevent a
health event or setback

Trained rare disease patient navigators or centralized
information sources
Increased awareness for the challenges facing rare
disease families
Additional research related to the experience of navigating the healthcare system and strategies to facilitate
better care

considerations. Additional policy recommendations are
explored in Table 3.

Limitations
MLD parent recruitment was more challenging based on
the estimated prevalence of the condition and the severity of the condition. Fewer parents of children with MLD
participated in the study, which may have limited the
understanding of parents’ experiences related to a disease
without an FDA approved treatment. There may have
been selection bias as individuals self-selected to participate in the study. Participants who enrolled may have been
more comfortable talking about insurance than those who
decided not to participate. Those who did not enroll may
have had more time constraints or stress that prevented

their participation. Additionally, individuals who were not
connected to the patient organizations would not have
seen the messages, which might mean our results overreport the importance of organizational support. It is possible that later enrollees of the study were encouraged by
earlier participants to enroll in the study. It is therefore
possible that these participants had similar experiences
and viewpoints as others who had already participated
in the study, further limiting the diversity of experiences
included.Study participants were more likely to be female,
live in the Southern U.S., and have at least a college degree.
It was not surprising that the majority of respondents were
female because mothers are most often the primary caregiver for children with rare diseases in the U.S. and are
often responsible for coordinating care for their child [75].
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Although two participants said they were not sure what
their monthly health insurance premium was because it
was automatically paid through their spouse’s paycheck,
no other gaps in knowledge about the child’s insurance
experience were apparent. U.S. Medicaid programs in
southern states tend to have stricter eligibility criteria
and fewer benefits, no regional pattern to the themes that
emerged was noted. The sample also included individuals
with higher educational attainment than the majority of
Americans, these individuals may have higher digital literacy or a higher comfort level with research which resulted
in them being more willing to participate in the study.
Families with lower educational attainment may experience even greater challenges interfacing with health insurers and obtaining recommended care (66). Further study
is needed to determine whether there may be additional
gaps in care coordination and health literacy that could be
addressed through health care policy.
None of the participants in the study were uninsured
or exclusively on public insurance, which could limit the
applicability of the model to those populations. Insurance status was self-reported and cannot be validated but
is likely accurate due to the level of involvement of most
parents with insurance companies and their representatives. Participants in this study discussed equipment and
therapy as these are key features in diseases with mobility issues, but other rare diseases are likely to have somewhat different needs. Finally, although we reached data
saturation in our interviews, it is possible that if more
interviews were conducted across a larger sample of the
population additional insights and themes might emerge.

Conclusion
Participants viewed insurance as just one component of a
larger puzzle that allows them to access necessary care for
their child. Insurance companies are often ill-equipped to
provide clear consistent answers on a disease they know
little about, forcing parents to meticulously track insurance benefits and interactions to balance medical needs
and financial stability. The complexity of the U.S. insurance system requires parents to enroll in multiple plans
to maximize coverage, an option that is not available for
all families. Individuals are often grateful for a supportive
network of peers and providers to identify program eligibility for additional assistance, but the final responsibility falls to them. There are policy initiatives that could
impact payment and delivery systems that could greatly
improve patient experience and outcomes. Incorporating the caregiver and patient perspective is critical in any
reform effort. Additional studies are needed to understand the full scope of barriers to care and policies that
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can facilitate better care access for families living with
rare diseases.
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